Highlights in the adjuvant treatment of colon cancer from annual meetings 2011
Tóm tắt
Từ khóa
Tài liệu tham khảo
André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27;3109–16.
Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combinded with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer. Results from NSABP C-07. J Clin Oncol. 2007;25:2198–2204.
Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with flurouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.
QUASAR Collaborative Group. Comparison of fluorouracil with additional levamisol, higher dose folinic acid or both as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet. 2000;355:1588–96.
Kabbinavar F, Hurwitz H, Fehrenbacher L, et al. Phase II randomized trial comparing bevacizumab plus fluorouracil/leucovorin with FU/LV in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5.
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
Saltz L, Diaz-Rubio E, Scheithauer W, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.
Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.
Bokemeyer C, Bondarenko I, Hartmann JT, et al. Overall survival of patients with KRAS wild-type tumors treated with FOLFOX4 ± Cetuximab as 1st-line treatment for metastatic colorectal cancer: the Opus study. ECCO-ESMO. 2009 (Abstract No. 6.079).
Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–4705.
Peeters M, et al. Randozmized phase III study of Panitumumab with fluorouracil, leucovorin and irinotectan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010;28:4706–13.
Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol. 2011; 29:11–6.
Allegra CJ, Yothers GA, O’Connell MJ, et al. Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer. J Clin Oncol. 2011;29 (ASCO Annual Meeting Abstracts, Abstract 3508).
André T, Van Cutsem E, Schmoll HJ, et al. A multinational, randomized phase III study of bevacizumab with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer: results and subgroup analyses from the AVANT trial. J Clin Oncol. 2011;29 (ASCO Annual Meeting Abstracts, Abstract 3509).
Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol. 2004;23:246 (Abstract 3500)
Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27:3117–25.
Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + Irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–80.
Huang J, Sargent DJ, Mahoney MR, et al. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147. Gastrointest Cancer Symp. 2011;28:18 (Abstract 363).
Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer : Results from NCCTG intergroup phase III trial N0147. J Clin Oncol. 2010;28:262 (Abstract CRA3507).
Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol. 2011;29:17–24.
Rosenberg R, Maak M, Simon I, et al. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer patients. J Clin Oncol. 2011;29 (Abstract 358).